Akeso Receives NMPA Clearance for First-in-Class Trispecific Antibody AK150 Trials

Key Facts

1Akeso's AK150 received Investigational New Drug (IND) clearance from China's NMPA for clinical trials.

2AK150 is currently the only ILT2/ILT4/CSF1R trispecific antibody under development globally.

3This is Akeso's first trispecific molecule to enter the clinical stage, targeting advanced solid tumors.

Akeso, Inc. (9926.HK) announced it has received Investigational New Drug (IND) clearance from China's National Medical Products Administration (NMPA) to begin clinical trials for AK150. AK150 is a first-in-class trispecific antibody targeting ILT2, ILT4, and CSF1R, specifically designed to treat advanced solid tumors. This milestone marks the first trispecific molecule from Akeso's proprietary technology platform to enter the clinical stage globally. The development aims to address resistance in current cancer immunotherapies through a unique triple-target approach. Investors view this as a significant expansion of the company's oncology pipeline and a validation of its advanced R&D capabilities. The upcoming clinical trials will focus on evaluating the safety and efficacy of the drug in patients with advanced malignancies.